 |
|
| Mary M. Zutter, M.D. |
Host-Tumor Interactions Research Program
The Host-Tumor Interaction Research (HT) Program focuses on the concept that tumor growth, invasion, and metastasis depend not only on the tumor cell alone but also on the complex interactions between the tumor cells and its “host.” The important role that the “microenvironment” of cells and tissue around the tumor plays in tumor biology provides an exceptional opportunity for novel therapeutic strategies.
Program Leader: Mary Zutter, Ph.D.
Scientific Goals
The overarching objective of the Host Tumor Interaction (HT) program is to define the interactions between tumor cells and the host, then develop strategies to target these interactions in order to control tumor progression and metastasis. The scientific goals fit into defining the role and mechanisms of the stromal cells, including the fibroblasts, endothelial and lymphatic elements, the matrix and the inflammatory/immune cells and/or the hematopoietic cells as critical targets for therapeutic intervention. Thus the scientific goals of the program are to:
- Identify molecules involved in communication between the tumor and host.
- Advance new reagents and techniques capable of validating a molecular therapeutic target (imaging techniques, antibodies, probes, genetically altered mice, small molecules, etc).
- Cultivate in vitro and in vivo model systems for proof-of-principle experimentation and testing of therapeutics.
- Foster interactions and collaborations that will accelerate these discoveries.
The HT Research Program focuses on the concept that tumor growth, invasion, and metastasis depend not on the tumor cell alone but on the complex interactions between the tumor cells and the host. The important role that the host microenvironment plays in tumor biology provides an exceptional opportunity for novel therapeutic strategies.
Program Focus to Meet Scientific Goals
The HT program focuses on the concept that tumor growth, invasion, and metastasis depend not on the tumor cell alone but on the complex interactions between the tumor cells and the host. The important role that the host microenvironment plays in tumor biology provides an exceptional opportunity for novel therapeutic strategies. The HT program was begun in 1996 and received an outstanding rating as a new program in the 1998 CCSG competing renewal. At the time of the previous submission, the specific interests of HT program members fell into the two broad areas of cell: cell and cell: matrix interactions and angiogenesis and vasculogenesis. We have maintained our solid research foundation in these areas, but also have expanded our areas of investigation with additional expertise in cell and molecular imaging, tumor invasion and metastasis, and immunology/hematology. Therefore, the program is focused on these five seminal areas of cancer biology. As shown in the description of the science outlined below, there is significant intellectual and project overlap between areas of interests within the HT program, as well as with other basic science programs and the organ-based cancer programs and SPORES.
In order to meet the scientific goals, the strategic goals/specific aims of the HT Program are to:
- Coordinate and catalyze collaborative work.
- Facilitate development of reagents, assays, and models to identify cellular and molecular components involved in host: tumor interaction.
- Identify funding opportunities related to the scientific focus areas.
- Mentor junior faculty members and develop the careers of new scientists examining the tumor microenvironment
- Interface program members with investigators outside Vanderbilt with common interests, including those with biotechnology and pharmaceutical perspectives
We have been extremely successful over the last five years of funding in developing and realizing these scientific goals. A graphic showing a sampling of program expertise and the four overlapping themes of the program is presented below.
Figure HT 1. Schematic showing general areas of research and interactions.
About the Program Leader
Mary M. Zutter, M.D. assumed the role of Program Leader of the Host-Tumor Interactions Program in the spring of 2004. She is Professor of Pathology and Cancer Biology, and Ingram Professor of Cancer Research. She received her M.D. from Tulane University School of Medicine and completed a residency and hematopathology fellowship training in the Departments of Pathology and Laboratory Medicine at the University of Washington. She was recruited to the faculty of the Vanderbilt University School of Medicine in 2003 from the Department of Pathology at Washington University School of Medicine. Dr. Zutter focuses on the role of cell adhesion molecules in host-tumor interactions. She has been funded continuously from the NIH for the last 17 years and is currently supported by three R01 grants from the NCI. Her laboratory focuses on the molecular basis of cell adhesion to collagen and its role in cancer biology. Much of this effort has been centered on the a2ß1 integrin. The a2ß1 integrin, a receptor for collagens, laminins, decorin, E-cadherin, MMP-1, endorepellin, angiocidin, and several viruses, has been implicated in normal developmental, inflammatory, and oncogenic processes. Her lab’s initial examination of integrin expression in human solid tumors revealed that the a2ß1 integrin was highly expressed in the epithelium of ducts and ductules of normal breast tissue. The work of the Zutter laboratory using detailed in vivo and in vitro model systems demonstrates that the a2ß1 integrin plays an important role in regulating tumor metastasis. Ongoing work focuses on the role of the a2ß1 integrin as a metastasis suppressor gene and the mechanisms by which the a2ß1 integrin mediates its anti-metastatic role when expressed either by the tumor cell, or functions as a metastasis efficiency modifier gene when expressed by cells of the microenvironment.
Dr. Zutter is on the Steering Committee for the Tumor Microenvironment subcommittee of the American Association of Cancer Research and is an associate editor of Cancer Research. She is a past member of both the Pathology B and Tumor Microenvironment Study Sections of the NCI/NIH. Dr. Zutter functions as the Director of Hematopathology within the Department of Pathology at Vanderbilt University School of Medicine. Her interests and expertise merge both basic science and clinical relevance to host-tumor interactions.
As HT Program Leader, Dr. Zutter contributes to organizing the yearly HT sponsored retreat. She instigated the program meetings on “Hot Topics” and organizes these mini-retreats. She is also responsible for hosting and coordinating the visits of guest speakers in areas of host tumor interactions. She focuses on identifying opportunities and catalyzing collaborations for pharmaceutical participation and she works in identifying funding opportunities that advance the goals of HT program members. She has played a role in decisions related to pilot funding of projects funded by both the CCSG and philanthropic gifts to the Cancer Center to fund young investigators. Dr. Zutter contributes to the strategic planning retreats and initiatives to define the future directions of VICC. She is instrumental in the recruitment of new faculty, including Drs. Zijlstra, Zinkel and Mosse to Vanderbilt and into the HT program. As the Program Leader, she also serves as a mentor to a number of the junior faculty both in the program and in other programs, including the Breast program. She is a mentor of Drs. Young (HT), Zinkel (ST), Mosse (HT), and Yankeelov (BC).
Areas of Research Program Expertise
HT program members focus on the cellular and molecular interactions between the tumor and the surrounding microenvironment that influence tumor development, growth, and progression. As discussed above, there has been a significant increase in the breadth and expertise within the HT program since the last review. At the time of the prior review there were two focus groups within the program: one focus was on cell: cell and cell: matrix interactions, including tumor cell invasion and metastasis; the second focus was on vasculogenesis/angiogenesis. We have maintained our solid research foundation in these areas, but also have expanded our areas of investigation with additional expertise. The two new areas include cell and molecular imaging, and inflammation/hematological malignancies. Both of the new areas have expanded rapidly during the previous funding period. The development of a focused and early program in hematological malignancies resulted from Dr. Zutter’s leadership. The realignment of the many faculty into and out of the Host-Tumor Interaction Program and the recruitment of new faculty has provided strong expertise and focus in each of these areas. Therefore, the program is now focused on these seminal, but overlapping areas of cancer biology — cell: cell and cell: matrix interactions including invasion and metastasis, inflammation and hematological malignancies, molecular imaging, and angiogenesis/vasculogenesis.
A review of the research interests and expertise of the members of each group are included below. Areas of overlap are numerous and will be pointed out in the write up.
Cell: cell and cell: matrix interactions
The focus of the HT program subgroup in cell: cell and cell: matrix interactions is to identify the molecules involved in communication between tumor cells and their cellular and structural microenvironment. The molecules being investigated fall into several broad classes, including growth factors and their receptors, extracellular matrix (ECM) and ECM-degrading proteases, and adhesion molecules and the associated cytoskeleton. The cellular components include blood-borne inflammatory/immune cells and resident fibroblasts, in addition to the focus on endothelial cells represented in the angiogenesis/vasculogenesis subgroup.
As evidence of the value added by VICC and the HT program, work in the area of cell: cell and cell: matrix interactions has resulted in the a development of two NHI funded centers, the Center for Matrix Biology and the Vanderbilt Center for Bone Biology. Funding for projects in this area, in addition to numerous R01s, include the PO1-CA40035 “Effects of Tumors on the Skeleton”; a U54 titled “Multistage Mathematical Modeling of Cancer Invasion”; and a U54 titled “Paracrine TGF-Beta Signaling in Tumor Initiation and Progression.” Each of these projects is discussed in more detail below.
Vanderbilt has a strong tradition in the discovery and characterization of growth factors and growth factor receptors that dates back to the discovery of EGF by Stanley Cohen. As highlighted below, Harold Moses, M.D. focuses on the interactions between TGFß and TGFß receptor signaling in the tumor stroma in modulating tumor progression of several epithelial cancers, including, pancreas, stomach and breast. Drs Moses, Matrisian, Lin, Carbone, and Richmond demonstrated that TGFß controls other cytokine networks including CXCR4 and SDF1, to stimulate the recruitment of Gr1+/CD11b positive, pro-tumorigenic inflammatory cells. Neil Bhowmick, Ph.D. and Simon Hayward, Ph.D. focus on the crosstalk between cytokines and chemokines, including TGFß in prostate differentiation and cancer. Dr. Hayward continues his work with tissue recombinants and has demonstrated the critical role tumor-associated fibroblasts and TGFß play in the development of prostate cancer. Many of these investigators work coordinately on understanding TGFß as a master regulator of host: tumor interactions through the NCI-supported Vanderbilt University Tumor Microenvironment Network (VUTMEN). As discussed in below, the successful request for funding via this network and participation in this national group was made possible by the close and collaborative work of the researchers within VICC. This is value added by the interactions sponsored by the CCSG and HT program.
Jin Chen, M.D., Ph.D. studies the role of another receptor tyrosine kinase, EphA2, in promoting breast cancer growth and metastasis. Her lab has recently identified the functional residues within the EphA2 receptor. Mark Boothby, M.D., Ph.D. focuses on the differentiation of T lymphoid cells mediated by IL-4 and downstream Stat6 signaling responses such as proliferation and lineage-specificity. Roy Zent, M.D., Ph.D. is interested in the interactions of TGFß with its receptor in K-ras-mediated transformation of mammary cancer.
Vanderbilt has assembled a group of matrix biology researchers that encompasses the Center for Matrix Biology. The Center for Matrix Biology is an interdepartmental group of basic and clinical scientists, whose research involves different aspects of biology of the extracellular matrices. The Center currently includes 44 members from 11 different departments. Their research interests include angiogenesis, biomaterials, tumor microenvironment, wound repair, fibrosis, and tissue regeneration. Many of the investigators focus on cancer and the tumor microenvironment. These include several members who were recruited to Vanderbilt at the time of the last review and have now had significant positive impact on the HT program. Vito Quaranta, M.D. arrived with a strong expertise in laminin and the interactions of laminin and integrins and their impact on tumor biology and cell motility. This expertise expanded to areas of mathematical modeling, and he oversees a U54 titled “Multiscale Mathematical Modeling of Cancer Invasion.” The Matrisian laboratory continues its longstanding interest in the role of matrix-degrading metalloproteinases (MMPs) in tumor progression. Dr. Matrisian’s interest in MMPs has been enhanced into molecular imaging and the prospect of translational analysis of MMP activity in vivo using a proteolytic nanobeacon.
The HT program also has considerable expertise in cell: cell and cell: matrix adhesion molecules. Ambra Pozzi, Ph.D. has defined the role of the collagen receptor integrin, the a1ß1 integrin in modulating tumor progression and initiation. Similarly, Dr. Zutter focuses on another collagen receptor integrin, the a2ß1 integrin and its role in tumor progression and metastasis. Alissa Weaver, M.D., Ph.D. brings an understanding of how tumor cell cytoskeleton responds to the microenvironment to stimulate invasion. Her work has demonstrated the critical role that cortactin plays in invadopodia formation and tumor cell invasion. Andries Zijlstra, Ph.D., a new recruit to Vanderbilt, has developed a novel chicken embryo model in which human alu PCR in conjunction with the chick embryo spontaneous metastasis assay can be used to quantify metastatic behavior of human tumor cells in vivo. He used this novel methodology in conjunction with a unique metastasis-blocking monoclonal antibody (mAb 1A5) to define the role of the tetraspanin CD151 in tumor cell dissemination.
Dr. Mundy was successful in development of the Vanderbilt Center for Bone Biology. The Center was established in July 2006 and now comprises 35 people, including 8 faculty, 6 postdoctoral fellows and 6 graduate students. There are two main areas of research: 1) the skeletal complications of cancer; and 2) cell biology of bone remodeling and fracture biology. Investigators in the Center for Bone Biology use a combination of in vitro and in vivo preclinical models to examine the mechanisms responsible for cancer spread to bone and its subsequent destruction, and the identification of potential drugs to inhibit this process of bone metastasis. The primary interests are in breast and prostate cancer metastasis, and in myeloma bone disease. Currently, Dr. Mundy and the other members of the Center are studying the molecular pathway responsible for increasing the expression of the tumor factor, the parathyroid hormone related peptide (PTHrP) in breast cancer, and have identified the Hedgehog signaling pathway as a latent development pathway in metastatic breast cancer cells that is activated as a consequence of metastasis and exposure of breast cancer cells to TGFß when cancer cells are present in the bone microenvironment. A collaboration between Dr. Mundy and the Vanderbilt School of Engineering is examining the effects that cancer has on the quality and fragility of bone. The goal is to carry out therapeutic studies in patients with metastatic breast cancer to improve their bone quality. These studies use state-of-the-art methods to examine bone quality, including Atomic Force Microscopy and Raman as well as FT-IR. Studies on osteoblast differentiation have focused on the BMP2 ligand signal transduction pathway. Dr. Mundy’s group has identified small molecular weight compounds that activate BMP2 transcription, and thereby mimic the effects of BMP2 on bone. They will investigate the compound’s therapeutic potential in bone mass restoration in patients with osteoporosis, traumatic fracture, and metastatic cancer. This work is supported by a number of federal grants, including an NCI program project grant in its 22nd year on the effects of tumors on the skeleton (PO1-CA40035) and an NCI R01 grant on the role of the Gli transcriptional activators on PTHrP expression. It also is supported by a project on the Breast Cancer SPORE (in collaboration with Drs. Arteaga and Moses) and a project on the VUTMEN grant (PI: Matrisian).
Angiogenesis/vasculogenesis
The HT group focus on angiogenesis/vasculogenesis has remained strong, with an interest in dissecting the molecular components that regulate the assembly of new blood vessels. There is significant overlap and crosstalk between investigators with interest in angiogenesis/vasculogenesis and inflammation/hematopoietic cells. Investigators from VICC have led the way in a number of exciting advances that demonstrate the importance of the hematopoietic/inflammatory system to tumor angiogenesis. Work from Charles Lin, Ph.D. published in Cancer Cell, demonstrated very early the importance of a population of myeloid immune suppressor (Gr+/CD11b+) cells in promoting tumor angiogenesis. This work was carried out in collaboration with Drs. Matrisian (HT), Shyr, and Carbone (T/HN). Additional work from his laboratory defined pathways downstream of angiopoietin/Tie2 signaling that lead to angiogenesis, including a role for Akt as a major angiogenic mediator. This work was a collaborative effort with Dr. Hallahan. Recently, Dr. Lin and Pierre Massion, M.D. (T/HN) showed that IkappaB kinase-alpha regulates endothelial cell motility and tumor angiogenesis. Both Drs. Zutter and Pozzi focus on the integrin family of cell adhesion receptors. Data from the Zutter laboratory revealed that the a2ß1 integrin, a collagen receptor, plays an important role in angiogenesis via regulation of VEGFR1 expression. The integrin-dependent angiogenic phenotype and tumor growth was dependent on specific interactions between the tumor cell and the genetically defined integrin repertoire of the host microenvironment. This work was carried out in collaboration with Dr. Pozzi. The altered angiogenic phenotype is not restricted to tumor vessels but also is observed in wound healing. Dr. Pozzi has focused on the role of another collagen receptor, the a1ß1 integrin in endothelial cell biology. The a1ß1 and the a2ß1 play distinct roles in endothelial cell biology. Dr. Chen’s expertise and interests also lie in both angiogenesis and cell-matrix interactions. As discussed below she has focused her research on the EphA2 receptor and ligands. EphA2 plays an important role not only in tumor angiogenesis, which she nicely demonstrated, but also in breast cancer progression. Dr. Hallahan focused on the development of immunotherapy targeted to radiation-inducible neoantigens within tumor vasculature. He utilized a phage display peptide library to identify peptides that bind to dead and dying cells within cancer following cytotoxic therapy. They identified a peptide that can be used to monitor cancer response to therapy. Pampee Young, M.D., Ph.D. has focused on the role of hematopoietic progenitor cells in tumor angiogenesis. Her work has shown that both VEGF and PLGF promote adult vasculogenesis by enhancing endothelial cell progenitor recruitment to the tumor vasculature. Takamune Takahashi, M.D., Ph.D. is interested in the regulation and control of endothelial cell growth by tyrosine phosphatases. Jason Jesson, Ph.D. a young investigator who recently joined the faculty and VICC, is using zebrafish as a model for understanding angiogenesis. He recently published a manuscript titled “Phospholipase D1 is required for angiogenesis of intersegmental blood vessels in zebrafish.”
A monthly meeting of investigators interested in angiogenesis/vasculogenesis has been ongoing for the last several years. All HT members involved in this area participate in these meetings.
Inflammation/Hematopathology
This new focus has grown tremendously during the last CCSG funding period. The reorganization of the Host-Tumor Interaction Program enhanced the expertise in inflammation and tumor immunology. The incorporation of area of hematopathology into the HT has created an extremely strong program with common interests and an even greater translational focus. The work of Ann Richmond, Ph.D. intersects chemokines, chemokine receptors, and the downstream signaling events that involve NFkappaB. Dr. Boothby’s research focuses on T cell regulation of the immune response as well as a novel protein, PARP-14, a member of the B aggressive lymphoma family, that transduces survival signals in B cells.
Drs. Van Kaer, Alcendor, Peek, and Ballard also have joined our program. Dr. Alcendor focuses on Kaposi’s sarcoma and Dr. Peek focuses on the role of Helicobacter pylori, inflammation and gastrointestinal cancer. His accomplishments are outlined later under Scientific Achievements. Dr. Peek was recently awarded an NCI program project grant that focuses on inflammation and cancer. Dr. Van Kaer focuses his research efforts on tumor immunology, NK cells and NKT cells, and their role in the innate immune response. His recent interest is in Invariant NKT (iNKT) cells, innate-like lymphocytes that recognize glycolipid antigens. Dr. Alcendor, a member of the HT and the Vanderbilt-Meharry Alliance, focuses on Kaposi’s sarcoma in HIV-positive patients. He also is interested in the role of viral infection in the pathogenesis of cancer. Dr. Ballard also focuses on the interaction between viruses and the immune system, including deregulation of cellular IkB Kinases by HTLV1 Tax. James Crowe, M.D. recently published a novel method for imaging mRNA in live cells by flow cytometric analysis. Addition of these investigators to the HT program has enhanced our commitment to understanding the positive and negative impact of inflammatory/immune cells in cancer. These changes have facilitated the growth of the focus group in inflammation within the HT.
Dr. Zutter has specific interest in hematopathology and is Director of the Division of Hematopathology. As the HT Program Leader, she has worked to develop a hematologic malignancy program within VICC. The strategic plan was initiated over a year ago to build a comprehensive, state-of-the-art hematologic malignancy research focus at Vanderbilt University School of Medicine. Our goal is to develop an internationally recognized program in hematologic malignancies, with three major themes:
- High-impact scientific discovery in research and translational biology of both adult and pediatric hematological diseases.
- Comprehensive clinical services in a state-of-the-art environment conducive to translational research.
- Education and mentoring of junior faculty, residents, post-doctoral candidates and students.
The strategic plan includes coordinating the collaborative work between the basic scientists in leukemia, lymphoma and multiple myeloma and the clinical-translational physicians. The ultimate goal is the development of breakthrough concepts, reagents, and models to attack these diseases. This will ultimately require significant funding resources both at the NIH level and from pharmaceutical companies. As part of the strategic plan, as a group we have defined the major focuses, i.e., leukemia, lymphoma and multiple myeloma. There is significant expertise in these areas at VICC, both in HT and in ST. Drs. Goodman, Greer, Jagasia, Kassim, Morgan, Mosse and Schuening bring exceptional expertise in both the treatment and pathobiology of hematological malignancies. Dr. Mundy’s bone program has a major focus on multiple myeloma. Other investigators involved in the hematological malignancy program reside in other basic science programs to facilitate cross-fertilization (e.g., Drs. Hiebert (ST and GM) and Brandt (ST)).
Cell and Molecular Imaging
The area of molecular imaging was a new addition to the program at the time of the last review. It is now a well-established and vibrant part of HT and includes the Vanderbilt In Vivo Cellular and Molecular Imaging Center, supported by a P50 grant. Dr. Gore has provided leadership for the Center in collaboration with Drs. Hallahan, Matrisian, Quarles, Caprioli, Coffey (GI) and Marnett (GM). Many of their accomplishments are detailed under Scientific Highlights. The collaborations between Drs. Gore and Caprioli have seen tremendous advancements in both basic science studies and in translational aspects through the merging of molecular, proteomic-based imaging with anatomical imaging (see below). The program has grown significantly with the addition of a number of young investigators with an interest in imaging science.
Program Members
- Abel, Ty William, M.D., Ph.D.
Assistant Professor of Pathology; Researcher - Alcendor, Donald J., Ph.D.
Assistant Professor; Researcher - Ballard, Dean W., Ph.D.
Professor; Researcher - Bhowmick, Neil A., Ph.D.
Assistant Professor; Researcher - Boothby, Mark R., M.D., Ph.D.
Professor of Microbiology and Immunology; Associate Professor of Medicine; Researcher - Bornhop, Darryl J., Ph.D.
Professor; Researcher - Caprioli, Richard M., Ph.D.
Stanley Cohen Professor of Biochemistry; Director of the Mass Spectrometry Research Center; Researcher - Chen, Jin, M.D., Ph.D.
Associate Professor of Medicine; Associate Professor of Cell and Development Biology; Associate Professor of Cancer Biology; Researcher - Clark, Peter E., M.D.
Associate Professor of Urologic Surgery; Urologic Oncologist - Crowe, James E., Jr., M.D.
Ingram Professor of Cancer Research; Professor of Pediatrics, Microbiology and Immuno.; Director, Vanderbilt Alliance for Nanomedicine; Director, Vanderbilt Program in Vaccine Sciences; Researcher - Dawant, Benoit, Ph.D.
Professor of Electrical Engineering; Professor of Biomedical Engineering; Professor of Radiology and Radiological Sciences; Researcher - Dhawan, Punita, Ph.D.
Assistant Professor; Researcher - Giorgio, Todd D., Ph.D.
Associate Professor of Biomedical Engineering; Associate Professor of Chemical Engineering; Researcher - Goodman, Stacey A., M.D.
Assoc Prof Med Stem Cell Transplant; Dir Marrow Transplant Unit; Hematologist/Oncologist - Gore, John C., Ph.D.
Professor; Director, Vanderbilt University Institute of Imaging Science; Researcher - Greer, John P., M.D.
Professor of Medicine and Pediatrics; Clinical Director, Hematology and Stem Cell Transplantation; Hematologist/Oncologist - Hamid, Rizwan, M.D., Ph.D.
Assistant Professor of Pediatrics; Researcher - Hanks, Steven K., Ph.D.
Professor; Researcher - Hayward, Simon W., Ph.D.
Associate Professor of Urologic Surgery and Cancer Biology; Researcher - Ho, Richard, M.D., MSCI
Assistant Professor; Pediatric Hematologist/Oncologist - Holt, Ginger E., M.D.
Assistant Professor; Orthopaedic Oncologist - Hudson, Billy G., Ph.D.
Elliot V. Newman Professor Med/Biochem; Dir, Ctr Matrix Biol; Researcher - Jagasia, Madan, M.D.
Assistant Professor; Hematologist/Oncologist - Jessen, Jason R., Ph.D.
Assistant Professor of Medicine; Assistant Professor of Cancer Biology; Researcher - Kassim, Adetola, M.D., M.S.
Asst Prof Med; Hematologist/Oncologist - Kaverina, Irina, Ph.D.
Assistant Professor of Cell and Developmental Biology; Researcher - Lin, P. Charles, Ph.D.
Associate Professor; Angiogenesis Researcher - Mahadevan-Jansen, Anita, Ph.D.
Assitant Professor of Biomedical Engineering; Researcher - Manning, H. Charles, Ph.D.
Assistant Professor of Radiology, Neurosurgery, Biomedical Engineering, Program in Chemical and Physical Biology; Researcher - Matrisian, Lynn M., Ph.D.
Professor and Chair, Cancer Biology; Researcher - Moots, Paul L., M.D.
Associate Professor of Neurology and Medicine; Neuro-Oncologist - Morgan, David, M.D.
Assistant Professor of Medicine (Hematology/Oncology); Hematologist/Oncologist - Moses, Harold L., M.D.
Director Emeritus; Hortense B. Ingram Professor of Molecular Oncology; Professor of Cancer Biology, Medicine and Pathology; Researcher - Mosse, Claudio A., M.D., Ph.D.
Assistant Professor; Pathologist - Mundy, Gregory R., M.D.
John A. Oates Chair in Translational Medicine; Director, Vanderbilt Center for Bone Biology; Professor of Medicine (Clinical Pharmacology), Pharmacology, Cancer Biology and Orthopaedics & Rehabilitation; Researcher - Ochieng, Josiah, Ph.D.
Professor of Cancer Biology; Researcher - Peek, Richard, Jr., M.D.
Director, Gastroenterology, Hepatology & Nutrition; Professor of Medicine (Gastroenterology, Hepatology, & Nutrition); Professor of Cancer Biology; Researcher - Pham, Wellington, Ph.D.
Assistant Professor of Radiology and Radiological Sciences; Researcher - Pozzi, Ambra, Ph.D.
Associate Professor of Medicine (Nephrology) and Cancer Biology; Researcher - Price, Ronald R., Ph.D.
Professor of Radiology and Radiological Sciences; Professor of Physics and Astronomy; Researcher - Quaranta, Vito, M.D.
Professor of Cancer Biology; Researcher - Quarles, C. Chad, Ph.D.
Assistant Professor of Radiology and Radiological Sciences; Researcher - Reddy, Nishitha, M.B.B.S.
Assistant Professor; Hematologist/Oncologist - Richmond, Ann W., Ph.D.
Professor of Cancer Biology and Medicine; Researcher - Roth, Bruce J., M.D.
Professor of Medicine and Urologic Surgery; The Paul V. Hamilton, M.D., and Virginia E. Howd Professor of Urologic Oncology; Section Chief, Solid Tumor Oncology; Co-Director, Genitourinary Oncology Program, Division of Hematology/Oncology; Medical Oncologist - Savani, Bipin N., M.D.
Assistant Professor of Medicine; Hematologist/Oncologist - Schuening, Friedrich, M.D.
Professor of Medicine; Section Chief, Hematology & Stem Cell Transplantation; Hematologist/Oncologist - Strickland, Stephen A., M.D.
Assistant Professor of Medicine; Hematologist/Oncologist - Takahashi, Takamune, M.D., Ph.D.
Assistant Professor of Medicine (Nephrology); Researcher - Thompson, Reid C., M.D.
Willaim F. Meacham Professor and Chairman of Neurological Surgery; Director of the Vanderbilt Brain Tumor Center; Director, Neurosurgical Oncology; Neurosurgical Oncologist - Van Kaer, Luc, Ph.D.
Professor of Microbiology & Immunology; Researcher - Weaver, Alissa, M.D. , Ph.D.
Associate Professor of Cancer Biology and Pathology; Researcher - Wikswo, John P., Jr., Ph.D.
Professor of Molecular Physiology and Biophysics; Professor of Biomedical Engineering and Physics; Gordon A Cain University Professor; Director, VIIBRE; Researcher - Yazlovitskaya, Eugenia M., Ph.D.
Research Assistant Professor; Radiation Oncologist - Young, Pampee, M.D., Ph.D.
Assistant Professor of Pathology; Assistant Professor of Medicine; Director of Transfusion Medicine; Researcher - Zent, Roy, M.D., Ph.D.
Assistant Professor of Medicine (Nephrology), Cancer Biology, and Cell & Developmental Biology; Researcher - Zijlstra, Andries, Ph.D.
Assistant Professor of Pathology; Assistant Professor of Cancer Biology; Researcher - Zutter, Mary M., M.D.
Director of Hematopathology; Ingram Professor of Cancer Research; Professor of Pathology, Cancer Biology, and Microbiology & Immunology; Pathologist
